A Novel Detection protocols for REliable prostate cancer Assays

Objective

The technology validation was successfully completed indicating a great commercial potential, and the innovative and inventive aspects of the assay platform are now covered by the filed priority European Patent Office (EPO) patent applications. Validated glycoprofiling of the proteins now uses lectins in a format, fully compatible with clinical PSA assay kits. This PoC grant focuses on 1. Pre-clinical retrospective validation of the early stage biomarker of prostate cancer (PCa) and 2. Commercialisation of the PCa diagnostics kit. Pre-clinical (60 human serum samples) is ongoing and retrospective validation study (450 human serum samples) of the assay will be performed by statistical analysis using a receiver operating characteristic (ROC) curve. The PoC describes all steps, which have been developed so far and all necessary steps, which need to be done for retrospective validation study, product development and commercialisation through our newly incorporated start-up Glycanostics Ltd. (www.glycanostics.com). We will provide PCa diagnostic test resulting in a second opinion to guide the right decision if the biopsy is needed. This will avoid the needless and unreliable biopsies and in the future rival an inaccurate PSA testing.

Field of science

• /natural sciences/biological sciences/biochemistry/biomolecules/proteins
• /medical and health sciences/clinical medicine/oncology/cancer
• /medical and health sciences/clinical medicine/oncology/cancer/prostate cancer

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)

Topic(s)

• ERC-2018-PoC - ERC Proof of Concept Grant

Call for proposal

ERC-2018-PoC
See other projects for this call

Funding Scheme

Host institution

Beneficiaries (2)